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Abstract
An association has been observed between indoor mold contamination and lung allergy and 
asthma. This relationship is not fully understood. 1→3-β-Glucan is the major cell wall component 
of fungi and a good marker of fungi exposure. The objective was to evaluate the adjuvant effect of 
zymosan, a crude yeast cell wall preparation of 1→3-β-glucan, during ovalbumin (OVA) 
sensitization in an allergy model. BALB/c mice were sensitized by pharyngeal aspiration with 
saline, 50 µg of OVA, or OVA with 1, 10, 50, or 75 µg of zymosan on days 0, 7, and 14. One 
week after sensitization, each sensitized animal group was challenged with an aspiration dose of 
50 µg of OVA once a week for 2 weeks. At 1 day after the last aspiration, bronchoalveolar lavage 
fluid and blood was collected, and markers of lung allergy and inflammation were assessed. An 
adjuvant effect of zymosan on OVA allergy during sensitization was observed as indicated by 
significant elevations in lung eosinophils, serum OVA-specific IgE, and lung IL-5 in the groups 
sensitized with zymosan and OVA. Pulmonary treatment with zymosan also amplified lung 
inflammation. Elevations were observed in lung neutrophils, TNF-α, and parameters of lung 
injury in the groups primed with both zymosan and OVA. In nearly all parameters, a non-linear 
dose–response relationship was observed in the groups primed with OVA and zymosan. The 
optimum adjuvant dose of zymosan was 10 µg. This study demonstrated an adjuvant effect of 
zymosan when exposures occurred during the sensitization phase in an OVA-induced allergy 
model in BALB/c mice.
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INTRODUCTION
Filamentous microfungi (mold) can become airborne and threaten human health after 
inhalation [1]. Both fungi and molds are ubiquitous and exist in the natural environment in 
indoor and outdoor settings. Water content (e.g., dampness) has been shown to promote 
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fungi growth [2]. Massive flooding or major water intrusion can trigger fungi and molds to 
grow exponentially, as was seen in more than 40% of the homes in New Orleans after 
Hurricane Katrina [3]. Exposure to elevated levels of mold and other microbial agents has 
been implicated in diseases associated with damp indoor environments and has become a 
major public concern in the indoor environment.
Repeated exposure to significant quantities of fungal material can result in respiratory 
irritation and allergic sensitization in some individuals [4]. Sensitized individuals may 
subsequently respond to much lower concentrations of airborne fungal material. Fungi and 
mold exposure has been associated with coughing, wheezing, chest tightness, shortness of 
breath, allergic reactions, hypersensitivity pneumonitis, and has been shown to exacerbate 
respiratory symptoms in sensitized asthmatics [3]. Importantly, mold levels in dust were 
associated with new-onset asthma among employees in a water-damaged building [5, 6]. 
The mechanisms by which mold and fungi induce asthma and allergic reactions have not 
been fully elucidated.
1→3-β-Glucans are the major cell wall constituents of fungi and have been considered as a 
biomarker for fungi exposure in the workplace [7]. Zymosan A is a commercially available 
yeast cell wall preparation containing β-glucan. The composition of Zymosan A has been 
reported to be ~70–75% total polysaccharide, ~13–17% protein, 0.8% chitin, 3–3.5% ash, 
and 6–7% fat [8]. Among the total polysaccharides, 50–57% are glucans and 16–22% are 
mannan. Zymosan has been shown to induce lung inflammation [9], alter adaptive immune 
response [10], and affect lung clearance of a bacterial pathogen [11, 12] after pulmonary 
treatment when evaluated using an animal model. In a comparison of the pulmonary 
inflammatory potential of different components of yeast and fungal cell walls, 1→3-β-
glucan was the most potent inflammatory agent tested, and zymosan, the crude B-glucan 
preparation, had a greater inflammatory activity than a partially purified particulate 1→3-β-
glucan [13]. In addition, specific β-glucans [14, 15] and soluble mold extracts [16] have 
been observed to have adjuvant effects in an allergic response to ovalbumin (OVA) in mice.
The goal of the current study was to further evaluate the adjuvant effect of zymosan, a crude 
yeast cell wall preparation containing β-glucan, during suboptimal lung OVA sensitization 
in a mouse allergy model. BALB/c mice were sensitized by pharyngeal aspiration with 
saline (vehicle control), OVA, or OVA with various doses of zymosan on days 0, 7, and 14. 
One week after sensitization, each sensitized animal group was challenged by pulmonary 
aspiration with OVA once a week for 2 weeks. At 1 day after the last aspiration, the 
presence of lung allergy, inflammation, and injury were assessed in the animals from the 
different treatment groups.
METHODS
Animals and Pulmonary Treatment
Specific pathogen-free male BALB/c mice (Charles River Lab, Wilmington, MA) were used 
in the experiments. BALB/c mice have a Th2-biased immune response, and have been 
described as developing evidence of allergy subsequent to OVA immunization [17]. All 
mice used in the study were treated according to an Animal Care and Use Committee 
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approved in-house animal protocol. The animals were housed in a room with restricted 
access and HEPA-filtered air, and were allowed to acclimate for 1 week before use in an 
animal facility approved by the Association for Assessment and Accreditation of Laboratory 
Animal Care. The mice were maintained on Harlan NIH-31, 6% irradiated diet, and tap 
water ad libitum. Beta-chips were used as bedding.
For the study, Zymosan A (Sigma-Aldrich Co., St. Louis, MO), a crude yeast cell wall 
preparation containing 1→3-β-glucan, was used. Mice (20–25 g) were sensitized 3 times 
(once a week for 3 weeks) by pharyngeal aspiration of 40 µL of sterile phosphate-buffered 
saline (PBS; vehicle control), a 50 µg solution of OVA (Sigma-Aldrich Co., St. Louis, MO), 
a 50 µg suspension of zymosan, or a combination of OVA (50 µg) + zymosan (1, 10, 50, and 
75 µg). One week after the third treatment, the groups of mice were challenged by 
pharyngeal aspiration with 50 µg OVA once per week for 2 weeks (see Figure 1 for a 
detailed diagram of the study’s dosing regimen). The treatment groups based on the above 
dosing schedule were designated as: (1) PBS–OVA, (2) OVA–OVA, (3) zym 50–OVA, (4) 
OVA+zym 1–OVA, (5) OVA+zym 10–OVA, (6) OVA+zym 50–OVA, and (7) OVA+zym 
75–OVA. It was the goal to produce a suboptimal sensitization response in the OVA–OVA 
group as compared to the PBS–OVA group to allow for the evaluation of a possible adjuvant 
effect of OVA+zym treatment.
The pharyngeal aspiration method was conducted according to Rao et al. [18]. Briefly, each 
mouse was anesthetized with isoflurane (Abbott Laboratories, North Chicago, IL). When 
fully anesthetized, the mouse was placed on a slanted board with the tongue gently pulled 
aside by small forceps. Then a 40 µL suspension of the different samples was pipetted at the 
base of the tongue, and tongue restraint was continued until at least 2 deep breaths were 
completed. This pharyngeal aspiration technique has been shown to provide a more even 
distribution of particles in the lung of mice than intratracheal instillation [18]. Mice (n = 12/
treatment group) were euthanized on day 29 at 1 day after the final treatment, and 
bronchoalvelar lavage (BAL) and blood collection were performed.
Whole Blood Collection and Bronchoalveolar Lavage
At 1 day after the final treatment on day 29, mice (n = 8/group) were deeply anesthetized 
with an intraperitoneal injection of sodium pentobarbital (> 100 mg/kg body weight; 
Sleepaway. Fort Dodge Animal Health, Wyeth, Madison, NJ). Whole blood was collected 
by cardio-puncture, and the animals were exsanguinated by severing the abdominal aorta. 
BAL was performed using 0.6 mL of Ca2+- and Mg2+-free cold PBS at pH 7.4. The first 
fraction of BAL fluid was retained in the lungs for 30 seconds with constant massaging of 
the lungs until collection. This first fraction of BAL fluid was centrifuged at 500 × g for 10 
minutes, and the supernatant was used for analyzing lactate dehydrogenase (LDH) activity, 
albumin, and cytokines levels. The lungs were further lavaged with 1-mL aliquots of PBS 
until a total of 5 mL BAL fluid was collected. These samples were also centrifuged for 10 
minutes at 500 × g, and the cell pellets from all washes for each mouse were combined and 
used for cell differentials. Total cell number was determined with a Multisizer 3 Coulter 
Counter (Beckman Coulter, Miami, FL).
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The murine anti-OVA IgE Ab was detected in serum samples collected from the treated 
animals using an IgE capture ELISA procedure modified from Hogan et al. [19]. The 
following reagents were used: monoclonal anti-mouse IgE (BD PharMingen, San Diego, 
CA), PBS/1% skim milk; OVA (25 mg/mL), rabbit anti-OVA-HRP conjugate (GenWay 
Biotech, San Diego, CA); and tetramethylbenzidine (Sigma-Aldrich Co., St. Louis, MO) 
substrate solution. After incubation for 10 minutes at room temperature, the reaction was 
stopped by adding 2N sulfuric acid and color development evaluated as OD450 using an 
automated plate reader.
Flow Cytometry: Whole Blood Differentiation and Quantification
One hundred µL of the red blood cell suspension was added into a flow cytometry tube with 
100 µL of 10% rat serum in FACS buffer for 10 minutes. Then, 50 µL of pre-mixed 
antibodies in FACS buffer was added to this tube and stained for 30 minutes at room 
temperature on a shaker. The antibody mix contained the final concentration of the 
following monoclonal antibodies: MHC II-FITC (2.5 µg/mL, 2G9), Gr-1-APC (2 µg/mL, 
RBC-8C5), CCR3-PE (0.625 µg/mL, 83.101.111), CD3-Per-CP (10 µg/mL, 145–2C11), 
B220-Per-CP (2 µg/mL, RA3–6B2), and NK1.1-PE (2 µg/mL, PK136). All the antibodies 
were purchased from PharMingen (Becton Dickinson, San Diego, CA) except CCR-3, 
which was purchased from R&D Systems (Minneapolis, MN). To prevent nonspecific 
binding to Fc receptors, 2.4G2 blocking reagent (6 µg/mL) was added to the monoclonal 
antibody mix. Red blood cells were lysed by adding 100 µL of Caltag Cal-lyse lying 
solution (GAS-010, Invitrogen, Carlsbad, CA) for 10 minutes in the dark and then adding 1 
mL of de-ionized water. The Caltag counting beads (PCB-100, Invitrogen, Carlsbad, CA) 
were added for cell enumeration prior to analysis in FACSCalibur (Becton Dickinson 
Biosystems, San Jose, CA). Samples were acquired through a live gate without 
compensation. After collecting 3500 counting beads, the data of all cells were exported to 
analysis software, FlowJo (Treestar, Costa Mesa, CA). The data were then analyzed 
according to the following gating strategy. First, leukocytes were separated by side 
scattering and forward scattering into 3 gates: lymphocytes, monocytes, and eosinophils + 
neutrophils. Lymphocytes were identified by FSC/SSC and expressing CD3 or B220. B cells 
were distinguished from T cells by MHC-II expression in lymphocytes gate. Eosinophils 
were defined as cells expressing the cotaxin receptor CCR3. Neutrophils were identified as 
cells expressing myeloid differentiation antigen Gr-1 and lack of CCR3 expression. 
Monocytes were identified by FSC/SSC and expressing Gr-1.
Flow Cytometry: Bronchoalveolar Lavage Cells Differentiation and Quantification
BAL cell differentiation was done according to Stevens et al. [20] with some modifications. 
BAL cells were re-suspended in 250 µL PBS, and 100 µL of the suspension was added into a 
flow cytometry tube with 100 µL of 10% rat serum in FACS buffer for 10 minutes. Then 50 
µL of pre-mixed antibodies in FACS buffer was added and cells were stained for 30 minutes 
at room temperature on a shaker. The mixture contained the final concentration of 5 µg/mL 
of the following antibodies: Fc block, Ly6G-FITC, Siglec-F-PE, CD45-PerCP, and CD11c-
APC. All the antibodies were purchased from PharMingen. The Caltag counting beads 
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(PCB-100, Invitrogen, Carlsbad, CA) were added for cell enumeration prior to analysis in 
FACSCalibur. Samples were acquired through a live gate without compensation. After 
collecting 4000 counting beads, the data of all cells were exported to the analysis software, 
FlowJo. The leukocytes were identified by cells expressing CD45+. Neutrophils were 
identified as cells expressing CD45+Ly6G+. Eosinophils were identified as cells expressing 
CD45+Siglec-F+ and macrophages were defined as cells expressing CD45+CD11c+.
Biochemical Parameters of Injury
Albumin content and LDH activity were measured in the acellular, first fraction of BAL 
fluid. These measures reflect the permeability of the bronchoalveolar-capillary barrier and 
general cytotoxicity, respectively. Albumin content was determined colorimetrically at 628 
nm based on albumin binding to bromcresol green using an albumin BCG diagnostic kit 
(Sigma-Aldrich Co., St. Louis, MO). LDH activity was determined by measuring the 
reduction of lactate to pyruvate coupled with the formation of NADH at 340 nm. 
Measurement was performed with a COBAS MIRA auto-analyzer (Roche Diagnostic 
System, Montclair, NJ).
BAL Fluid Cytokines
Analysis of cytokines in the acelluar BAL fluid was conducted using a Mouse Th1/Th2 
Cytokine Kit (BD Biosciences, San Diego, CA) and was analyzed on a FACSCalibur flow 
cytometer. Standard curves were determined for each cytokine, ranging from 20 pg/mL to 
5000 pg/mL. The lower limit of detection of the assay was 2.5–6.3 pg/mL, depending on the 
cytokine. The following cytokines were measured: interleukin-2 (IL-2), interleukin-4 (IL-4), 
interleukin-5 (IL-5), interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). Only the 
cytokines (e.g., IL-5, TNF-α) that had a significantly different response from the OVA–
OVA group are presented.
Lung Histopathology
A separate set of non-lavaged BALB/c mice (n = 4/group) from each treatment group were 
reserved for lung histopathology analysis. The lungs were inflated and fixed with 10% 
neutral buffered formalin for a minimum of 24 hour. The left lung lobes were embedded as 
individual lobes in paraffin, and then a 5 µm standard section was cut. Slides were stained 
with hematoxylin and eosin and interpreted by a contracted board certified veterinary 
pathologist in a blinded fashion for morphological changes related to lung allergy, injury, 
and inflammation. If abnormal changes were found, severity was scored as follows: 0 = 
normal (change not present), 1 = minimal, 2 = mild, 3 = moderate, 4 = marked, and 5 = 
severe.
Statistical Analysis
All data are presented as means ± standard error (SE) of measurement. Differences were 
considered statistically significant at P < 0.05. Statistical analyses for Figures 2–6 were 
performed using SigmaStat v3.11 software (Systat Software, Inc., Chicago, IL). An analysis 
of variance (ANOVA) with the Student-Newman-Keuls post-hoc test was used for 
comparing the different treatment groups. The statistical analyses for the lung 
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histopathology scores (data not shown) were conducted using SAS/STAT software, Version 
9.1, of the SAS System for Windows (SAS Institute, Inc., Cary, NC). Histopathology 
severity scores were analyzed using an omnibus Kruskal-Wallis nonparametric test followed 
by pairwise comparisons using the Wilcoxon rank-sum test.
RESULTS AND DISCUSSION
The objective of the current study was to evaluate the adjuvant effect of zymosan, a crude 
yeast cell wall preparation containing β-glucan, during suboptimal lung OVA sensitization 
in a mouse allergy model. Multiple studies have shown that different preparations or extracts 
of 1→3-β-glucan have potential adjuvant effects in mouse models of allergy. Ormstad et al. 
[15] demonstrated that a crude β-glucan suspension extracted from barley enhanced a Th2-
dependent antibody response to OVA, as indicated by increased levels of IgE and IgG1 
compared to OVA. In a related investigation, Instanes et al. [16] observed that soluble 
extracts of different molds had adjuvant effects on the allergic response to OVA in mice. 
Wan et al. [14] utilized an airway OVA mouse allergy model by which animals were 
sensitized by an aerosolized crude β-glucan extract and OVA. They observed that the crude 
β-glucan preparation induced Th2-mediated responses by abrogating inhalation-induced IgE 
down-regulation and promoting airway eosinophil infiltration to inhaled antigen. In contrast, 
using a similar design by which animals were co-exposed to OVA by inhalation, Rylander 
and Holt [21] showed that a crude β-glucan suppressed OVA-induced antibody formation 
and eosinophilia, as well as abolished the stimulation of OVA-induced antibody production 
by endotoxin (lipopolysaccharide).
Multiple parameters of lung allergy, inflammation, and injury were examined in the blood 
and BAL fluid of mice from the different treatment groups 1 day after the final OVA 
challenge on day 29 of the dosing regimen in the current study (Figure 1). Eosinophil influx 
into the lungs, indicative of a local allergic response, indicated that a suboptimal level of 
sensitization was achieved as the OVA–OVA group was significantly elevated above the 
PBS–OVA group (Figure 2A). An adjuvant effect of zymosan on OVA allergy also was 
observed as evidenced by significant elevations in lung eosinophils in the OVA+zym–OVA 
groups compared to the OVA–OVA group (Figure 2A). In regards to the systemic response, 
the adjuvant effect was not as dramatic. The combination of OVA and zymosan priming in 
the lungs did not cause a statistically significant increase in peripheral blood eosinophil 
numbers compared to the OVA–OVA group (Figure 2B).
Further evidence for an adjuvant effect of zymosan on OVA allergy was observed in that 
serum OVA-specific IgE was significantly increased at all concentrations in the OVA+zym–
OVA groups compared to OVA–OVA group (Figure 3). A similar trend was observed when 
evaluating the BAL fluid concentrations of IL-5 (Figure 4). Allergy in both humans and 
animal models has been shown to be caused by polarization of CD4+ T-helper lymphocytes 
to the Th2 subclass [22]. IL-5 is a marker for the Th2 phenotype and has an important role in 
allergy. IL-5 is involved in the differentiation and maturation of eosinophils and in the 
migration of eosinophils to tissue sites in the presence of an allergic response and has been 
identified across animal models as being a key common denominator in allergic 
inflammatory pathways [23–25].
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The current study differs from similar previous animal studies in that zymosan, an insoluble, 
particulate form of crude β-glucan, was shown to have a strong adjuvant effect. Ormstad et 
al. [15] indicated that the adjuvant effect of an insoluble β-glucan had a much less 
pronounced adjuvant effect than a soluble form of β-glucan. Our group has previously 
demonstrated that insoluble crude β-glucan, but not soluble crude β-glucan, induced the 
majority of pulmonary inflammation, injury, and irritation (e.g., increased breathing 
frequency) in an animal model [26]. Also, the results of the current study differ from the 
findings of the investigation by Rylander and Holt [21]. The reasons for the contradictory 
results may be due to the dose levels and pulmonary treatment methods used in the studies. 
In the current study, a pulmonary aspiration dose, 1–75 µg of zymosan, was used compared 
to an inhalation dose of 8 pg/m3 for 4 hour/day for 5 days/week for 5 weeks in the study of 
Rylander and Holt [21]. The rationale for the doses chosen in the current study was based on 
the fact that no response was observed below 1 µg pharyngeal aspiration dose of zymosan in 
preliminary experiments. It is important to note that realistic environmental exposures range 
from 1 ng/kg to 5 ng/kg body weight [27].
It has been reported that zymosan has distinct biological activities compared to purified 
yeast particulate 1→3-β-glucan [13]. A recent study by Huang et al. [28] indicated that the 
adjuvant activity of purified 1→3-β-glucan led to a Th1/Th17 response, and not the Th2 
response as reported in this paper and by others [14–16] for zymosan, further differentiating 
the activities of 1→3-β-glucan from zymosan. It was observed that OVA-loaded purified β-
glucan particles induced strong humoral and Th1- and Th17-dependent CD4+ T-cell 
responses in mice. This difference in immune response may be due to the fact that zymosan 
also is composed of a significant amount of mannan, which is a highly immunogenic 
polysaccharide. Mannan is an important fungal cell wall antigen responsible for the 
specificity of different serologic reactions and induction of humoral responses [29, 30]. 
Because of the presence of mannan, chitin, β-glucan, and other components of zymosan, a 
study is needed that examines the influence these other fungal cell wall components 
individually have on the allergy/ adjuvant dose response observed in the current study.
Evidence of an adjuvant effect of zymosan on inflammation also was observed by 
significant elevations in lung neutrophils (Figure 5A), blood neutrophils (Figure 5B), and 
BAL fluid concentrations of TNF-α (Figure 6) compared to the OVA–OVA group. In 
addition, OVA and zymosan priming caused a significant increase in lung injury as 
determined by LDH activity and albumin concentrations in the BAL fluid (data not shown). 
Previously, our group has shown that pulmonary exposure to particulate zymosan increased 
lung neutrophil influx, LDH activity, and alveolar macrophage activation [26]. Others have 
shown that different lung pro-inflammatory agents, such residual oil fly ash [31, 32], diesel 
exhaust particles [33], ambient particulate matter [34, 35], and house dust mites [36] have 
adjuvant effects in animal respiratory allergy models.
The lung histopathologic changes in the current study were consistent with an allergic 
response after OVA challenge and included perivascular, peribronchiolar, and alveolar 
eosinophilic infiltrates, as well as goblet cell hyperplasia. Minimal to mild intimal changes 
were noted in pulmonary vessels in many mice, associated with surrounding inflammation. 
These changes included intimal thickening, endothelial cell hypertrophy, and leukocyte 
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infiltration, probably due to emigration of leukocytes. In the mice primed with 50 mg of 
zymosan only then challenged with OVA, the bronchiolar epithelium was normal and there 
was no eosinophil or lymphocyte infiltration around either the vessel on the left or the one 
on the right (Figure 7A). In the group primed with OVA then challenged with OVA, the 
bronchiole epithelium is shown to be lined with an increase in goblet cells (Figure 7B). The 
surrounding alveoli appeared empty and free of leukocytes.
However, in mice primed with OVA + zymosan (10 µg) then challenged with OVA, the 
bronchioles were lined almost entirely by goblet cells (e.g., goblet cell hyperplasia) and 
surrounded by a mild infiltration of leukocytes (Figure 7C). Leukocyte infiltration was 
present around a blood vessel, in thickened alveolar septa, and within alveolar lumina. In the 
group primed with OVA+zymosan (50 µg) then challenged with OVA, bronchioles were 
observed to have diffused goblet cell hyperplasia, and there were thick band of lymphocytes 
and eosinophils that encircled pulmonary vessels (Figure 7D). In addition, alveolar septa 
were thickened and contained increased numbers of macrophages and eosinophils. Similar 
changes in lung architecture and lung cell and inflammatory responses previously have been 
observed after exposure to residual oil fly ash particles [37] and urban air particulate matter 
[38] in an allergic pulmonary inflammation model.
In ranking the severity of the histopathologic changes, statistically significant increases were 
observed for perivascular lymphocyte infiltration in the OVA+zym 10–OVA, OVA+zym 
50–OVA, and OVA+zym 75–OVA groups compared to the OVA–OVA group (data not 
shown). In addition, the severity of alveolar neutrophil–eosinophil and histiocytic infiltrates 
was significantly increased in the OVA+zym 10–OVA group compared to the OVA–OVA 
group. Peribronchiolar lymphocyte infiltration was significantly increased, in terms of 
severity, in the OVA+zym 75–OVA group compared to the OVA–OVA group.
In most cases, the changes in lung histopathology followed the same non-linear, bell-shaped 
zymosan dose–response relationship as the BAL parameters of allergy, inflammation, and 
injury for the OVA+zym–OVA groups. For every parameter except lung neutrophils, the 
response peaked in the group primed with OVA + 10 µg zymosan with the response 
returning towards OVA–OVA levels in the group primed with OVA + 75 µg zymosan. A 
phenomenon that is common in allergy studies has been the observation that greater 
adjuvant responses occur at lower doses compared to higher doses. Instanes et al. [16] 
indicated that the adjuvant effect of mold extracts was most pronounced at the lowest dose 
(12.5 µg) examined, which was comparable to the peak adjuvant dose of 10 µg of zymosan 
in the current study.
Human studies also have observed a similar dose–response adjuvant effect. A significant, 
non-linear relationship between endotoxin exposure and a number of common allergens was 
seen in adult pig farmers as the risk of sensitization was strongly decreased with increasing 
exposure to endotoxin [39]. Schram-Bijkerk et al. [40] observed similar findings in house 
dust mites and mite sensitization in farming and non-farming children. Interestingly, 
exposure to high levels of crude sources of β-glucans was observed to be associated with 
decreased risk for recurrent wheezing among infants [41, 42], indicating that β-glucan 
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exposure may protect against asthma development. This protective effect is believed to be 
due to microbial exposure early in life and development of tolerance.
CONCLUSIONS
In the current study, we assessed the potential for particulate fungi and yeast, as tested using 
zymosan, for the observed adjuvant activity during the sensitization phase in a mouse model 
of asthma. This response was characterized by increased eosinophils in the lungs as well as 
elevations in IgE and IL-5 levels after sensitization with a combination of zymosan and 
OVA compared to sensitizing with OVA alone. Pulmonary treatment with zymosan also 
amplified lung inflammation and injury in the OVA allergy model. Elevations were 
observed in lung neutrophils, TNF-α, and biochemical parameters of lung injury in the 
groups primed with both zymosan and OVA. In nearly all parameters assessing lung allergy 
and inflammation, a non-linear dose–response relationship was observed in the groups 
primed with a combination of OVA and different doses of zymosan, a phenomenon that is 
commonly observed in the assessment of allergic responses. A study is needed that 
examines the influence of other fungal cell wall components, such as mannan and chitin as 
well as purified β-glucan, on the allergy/adjuvant response to OVA observed in the current 
study. The findings from this study may be useful in evaluating the pulmonary allergic and 
asthmatic responses observed in non-sensitized and sensitized individuals who live or work 
in areas that are contaminated with dusts that contain yeast and molds with high levels of 
crude β-glucans.
Acknowledgments
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the 
National Institute for Occupational Safety and Health.
ABBREVIATIONS
ANOVA Analysis of variance
BAL Bronchoalveolar lavage









SE Standard error of measurement
Young et al. Page 9















1. Soloman GM, Hjelmroos-Koski M, Rotkin-Ellma M, Hammond SK. Airborne mold and endotoxin 
concentrations in New Orleans, Louisiana, after flooding, October through November 2005. 
Environ Health Perspect. 2006; 114:1381–1386. [PubMed: 16966092] 
2. Institute of Medicine. Damp Indoor Spaces and Health. Washington, DC: National Academies 
Press; 2004. Human health effects associated with damp indoor environments; p. 183-269.
3. Centers for Disease Control and Prevention. Health concerns associated with mold in water-
damaged homes after Hurricane Katrina and Rita, New Orleans area, Louisiana, October 2005. 
MMWR Morbid Mortal Wkly Rep. 2006; 55:41–44.
4. Bush RK, Portnoy JM, Terr AI, Wood RA. The medical effects of mold exposure. J Allergy Clin 
Immunol. 2006; 117:326–333. [PubMed: 16514772] 
5. Park J-H, Cox-Ganser J, Rao C, Kreiss K. Fungal and endotoxin measurement in dust associated 
with respiratory symptoms in a water-damaged office building. Indoor Air. 2006; 16:192–203. 
[PubMed: 16683938] 
6. Park J-H, Cox-Ganser JM, Kreiss K, White SK, Rao CY. Hydrophilic fungi and ergosterol 
associated with respiratory illness in a water-damaged building. Environ Health Perspect. 2008; 
116:45–50. [PubMed: 18197298] 
7. Rylander R. Investigations of the relationship between disease and airborne (1→3)-β-D-glucan in 
buildings. Mediators Inflamm. 1997; 6:275–277. [PubMed: 18472858] 
8. DiCarlo FJ, Fiore JV. On the composition of zymosan. Science. 1957; 127:756–757.
9. Young S-H, Robinson VA, Barger M, Porter DW, Frazer DG, Castranova V. Acute inflammation 
and recovery in rats after intratracheal instillation of a 1→3-β-glucan (Zymosan A). J Toxicol 
Environ Health A. 2001; 64:311–325. [PubMed: 11693490] 
10. Young S-H, Roberts JR, Antonini JM. Pulmonary exposure to 1→3-β-glucan alters adaptive 
immune responses in rats. Inhal Toxicol. 2006; 18:865–874. [PubMed: 16864404] 
11. Young S-H, Antonini JM, Roberts JR. Single pre-exposure to high dose of zymosan enhances lung 
defense mechanisms and accelerates the pulmonary clearance of a bacterial pathogen in rats. Exp 
Lung Res. 2008; 34:559–578. [PubMed: 19005921] 
12. Young S-H, Antonini JM, Roberts JR. Preexposure to repeated low doses of zymosan increases the 
susceptibility to pulmonary infection in rats. Exp Lung Res. 2009; 35:570–590. [PubMed: 
19842846] 
13. Young S-H, Ostroff GR, Zeidler-Erdely PC, Roberts JR, Antonini JM, Castranova V. A 
comparison of the pulmonary inflammatory potential of different components of yeast cell wall. J 
Toxicol Environ Health. 2007; 70:116–124.
14. Wan G-H, Li C-S, Guo S-P, Rylander R, Lin R-H. An airborne mold-derived product, β-1,3-D-
glucan, potentiates airway allergic responses. Eur J Immunol. 1999; 29:2491–2497. [PubMed: 
10458763] 
15. Ormstad H, Groeng E-C, Lovik M, Hetland G. The fungal cell wall component β-1,3-glucan has an 
adjuvant effect on the allergic response to ovalbumin in mice. J Toxicol Environ Health A. 2000; 
61:55–67. [PubMed: 10990163] 
16. Instanes C, Ormstad H, Rydjord B, Wiker HG, Hetland G. Mould extracts increase the allergic 
response to ovalbumin in mice. Clin Exp Allergy. 2004; 34:1634–1641. [PubMed: 15479281] 
17. Pauluhn J, Mohr U. Experimental approaches to evaluate respiratory allergy in animal models. Exp 
Toxicol Pathol. 2005; 56:203–234. [PubMed: 15816351] 
18. Rao GV, Tinkle S, Weissman DN, Antonini JM, Kashon ML, Salmen R, Battelli LA, Willard PA, 
Hoover MD, Hubbs AF. Efficacy of a technique for exposing the mouse lung to particles aspirated 
from the pharynx. J Toxicol Environ Health A. 2003; 66:1441–1452. [PubMed: 12857634] 
Young et al. Page 10













19. Hogan MB, Weissman DN, Hubbs AF, Gibson LF, Piktel D, Landreth KS. Regulation of 
eosinophilopoiesis in a murine model of asthma. J Immunol. 2003; 171:2644–2651. [PubMed: 
12928418] 
20. Stevens WW, Kim TS, Pujanauski LM, Hao X, Braciale TJ. Detection and quantitation of 
eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods. 2007; 327:63–
74. [PubMed: 17716680] 
21. Rylander R, Holt PG. (1→3)-β-D-glucan and endotoxin modulate immune response to inhaled 
allergen. Mediators Inflamm. 1998; 7:105–110. [PubMed: 9836497] 
22. Katelaris CH, Linneberg A, Magnan A, Thomas WR, Wardlaw AJ, Wark P. Developments in the 
field of allergy in 2010 through the eyes of Clinical and Experimental Allergy. Clin Exp Allergy. 
2011; 41:1690–1710. [PubMed: 22107142] 
23. Inman MD. Bone marrow events in animal models of allergic inflammation and 
hyperresponsiveness. J Allergy Clin Immunol. 2000; 106:S235–S241. [PubMed: 11080737] 
24. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for 
therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012; 42:712–737. 
[PubMed: 22092535] 
25. Poon AH, Eidelman DH, Martin JG, Laprise C, Hamid Q. Pathogenesis of severe asthma. Clin Exp 
Allergy. 2012; 42:625–637. [PubMed: 22515387] 
26. Young S-H, Robinson VA, Barger M, Whitmer M, Porter DW, Frazer DG, Castranova V. 
Exposure to particulate 1→3-β-glucan induces greater pulmonary toxicity than soluble 1-> 3-beta-
glucans in rats. J Toxicol Environ Health A. 2003; 66:25–38. [PubMed: 12587289] 
27. Rylander R. Organic dust induced pulmonary disease: the role of mould derived B-glucan. Ann 
Agric Environ Med. 2010; 17:9–13. [PubMed: 20684476] 
28. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Robust stimulation of humoral and cellular 
immune responses following vaccination with antigen-loaded β-glucan particles. mBio. 2010; 
1(3):e00164–e00110. [PubMed: 20802824] 
29. Martinez JP, Gil ML, Lopez-Ribot JL, Chaffin WL. Serologic responses to cell wall 
mannoproteins and proteins of Candida albicans. Clin Microbiol Rev. 1998; 11:121–141. 
[PubMed: 9457431] 
30. Kedzierska P, Kochan P, Pietrzyk A, Kedzierska J. Current status of fungal cell wall components 
in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and 
(1→3)-β-D-glucan antigens. Eur J Clin Microbiol Infect Dis. 2007; 26:755–766. [PubMed: 
17671803] 
31. Gavett SH, Madison SL, Stevens MA, Costa D. Residual oil fly ash amplifies allergic cytokines, 
airway responsiveness, and inflammation in mice. Am J Respir Crit Care Med. 1999; 160:1897–
1904. [PubMed: 10588603] 
32. Lambert AL, Dong W, Selgrade MK, Gilmour MI. Enhanced allergic sensitization by residual oil 
fly ash particles is mediated by soluble metal constituents. Toxicol Appl Pharmacol. 2000; 
165:84–93. [PubMed: 10814556] 
33. Al-Humadi NH, Siegel PD, Lewis DM, Barger MW, Ma JYC, Weissman DN, Ma JKH. The effect 
of diesel exhaust particles (DEP) and carbon black on thiol changes in pulmonary ovalbumin 
allergic sensitized Brown Norway rats. Exp Lung Res. 2002; 28:333–349. [PubMed: 12097228] 
34. Morishita M, Keeler GJ, Wagner JG, Marsik FJ, Timm EJ, Dvonch JT, Harkema JR. Pulmonary 
retention of particulate matter is associated with airway inflammation in allergic rats exposed to air 
pollution in urban Detroit. Inhal Toxicol. 2004; 16:663–674. [PubMed: 15371055] 
35. Steerenberg PA, Withagen CET, van Dalen WJ, Dormans JAMA, Cassee FR, Heisterkamp SH, 
van Loveren H. Adjuvant activity of ambient particulate matter of different sites, sizes, and 
seasons in a respiratory allergy mouse model. Toxicol Appl Pharmacol. 2004; 200:186–200. 
[PubMed: 15504455] 
36. Lambert AL, Dong W, Winsett DW, Selgrade MK, Gilmour MI. Residual oil fly ash exposure 
enhances allergic sensitization to house dust mite. Toxicol Appl Pharmacol. 1999; 158:269–277. 
[PubMed: 10438660] 
37. Arantes-Costa FM, Lopes FDTQS, Toldeo AC, Magliarelli-Filho PA, Moriya HT, Carvalho-
Oliveira R, Mauad T, Saldiva PHN, Martins MA. Effects of residual oil fly ash (ROFA) in mice 
Young et al. Page 11













with chronic allergic pulmonary inflammation. Toxicol Pathol. 2008; 36:680–686. [PubMed: 
18477768] 
38. Wagner JG, Morishita M, Keener GJ, Harkema JR. Divergent effects of urban particulate air 
pollution on allergic airway responses in experimental asthma: a comparison of filed exposure 
studies. Environ Health. 2012; 11:45. [PubMed: 22768850] 
39. Portengen P, Preller L, Tielen M, Doekes G, Heederik D. Endotoxin exposure and atopic 
sensitization in adult pig farmers. J Allergy Clin Immunol. 2005; 115:797–802. [PubMed: 
15806001] 
40. Schram-Bijikerk D, Doekes G, Boeve M, Douwes J, Riedler J, Ublagger E, von Mutius E, Budde J, 
Pershagen G, van Hage M, Wickman M, Braun-Fahrländer C, Waser M, Brunekreef B. 
PARSIFAL Study Group. Nonlinear relations between house dust mite allergen levels and mite 
sensitization in farm and nonfarm children. Allergy. 2006; 61:640–647. [PubMed: 16629797] 
41. Douwes J, van Strien R, Doekes G, Smit J, Kerkhof M, Gerritsen J, Postma D, de Jongste J, 
Travier N, Brunekreef B. Does early indoor microbial exposure reduce the risk of asthma? The 
prevention and incidence of asthma and mite allergy birth cohort study. J Allergy Clin Immunol. 
2006; 117:1067–1073. [PubMed: 16675334] 
42. Iossifova YY, Reponen T, Bernstein DI, Levin L, Kalra H, Campo P, Villareal M, Lockey J, 
Hershey GK, LeMasters G. House dust (1–3)-beta-d-glucan and wheezing in infants. Allergy. 
2007; 62:504–513. [PubMed: 17441791] 
Young et al. Page 12














Experimental design: dosing schedule. BALB/c mice were sensitized by pharyngeal 
aspiration (PA) with PBS, OVA (50 µg), zymosan (50 µg), or a combination of OVA (50 µg) 
+ zymosan (1, 10, 50, and 75 µg) once a week for 3 weeks (n = 12). One week later, these 
groups of mice were challenged by PA with 50 µg OVA once a week for 2 weeks. All mice 
were euthanized 1 day after the final treatment on day 29. The treatment groups based on the 
above dosing schedule were designated as: (1) PBS–OVA, (2) OVA–OVA, (3) OVA+zym 
1–OVA, (4) OVA+zym 10–OVA, (5) OVA+zym 50–OVA, (6) OVA+zym 75–OVA, and 
(7) zym 50–OVA.
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Allergic response: (A) lung eosinophils, and (B) blood eosinophils recovered from the 
bronchoalveolar lavage fluid (BALF) and blood at 1 day after the final treatment. Values are 
means ± SE of 8 mice per exposure group; *indicates significant increase (P < 0.05) versus 
the PBS–OVA group; #indicates a significant increase (P < 0.05) versus the OVA–OVA 
group.
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OVA-specific IgE levels in the blood serum. Values are means ± SE of 8 mice per exposure 
group; #indicates a significant increase (P < 0.05) versus the OVA–OVA group.
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Pro-allergenic cytokine: IL-5 in the acellular bronchoalveolar lavage fluid (BALF) at 1 day 
after the final treatment. Values are means ± SE of 8 mice per exposure group; #indicates a 
significant difference (P < 0.05) versus the OVA–OVA group.
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Inflammatory neutrophilic response: (A) lung neutrophils, and (B) blood neutrophils 
recovered from the bronchoalveolar lavage fluid (BALF) and blood at 1 day after the final 
treatment. Values are means ± SE of 8 mice per exposure group; *indicates significant 
increase (P < 0.05) versus the PBS–OVA group; #indicates a significant increase (P < 0.05) 
versus the OVA–OVA group.
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Pro-inflammatory cytokine: TNF-α in the acellular bronchoalveolar lavage fluid (BALF) at 
1 day after the final treatment. Values are means ± SE of 8 mice per exposure 
group; #indicates a significant increase (P < 0.05) versus the OVA–OVA group.
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Lung histopathology: (A) Mice were sensitized with zymosan (50 mg) then challenged with 
OVA. (B) Mice were sensitized with OVA then challenged with OVA. (C) Mice were 
sensitized with OVA + zymosan (10 µg) then challenged with OVA. (D) Mice were 
sensitized with OVA + zymosan (50 µg) then challenged with OVA. Micron bar = 200 µm; 
br = bronchiole; bv = blood vessel; gc = goblet cell; *= leukocyte infiltration.
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